Although it's popular as a coronavirus stock these days, Abbot Laboratories (NYSE:ABT) nevertheless is struggling with other areas of its business. This was revealed in the company's second quarter of fiscal 2020 results, which it published Thursday morning.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,